Actively Recruiting
The Texas Interprofessional Pharmacogenomics (IPGx)
Led by Texas A&M University · Updated on 2025-09-12
50
Participants Needed
1
Research Sites
306 weeks
Total Duration
On this page
Sponsors
T
Texas A&M University
Lead Sponsor
I
InnovativeGx
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.
CONDITIONS
Official Title
The Texas Interprofessional Pharmacogenomics (IPGx)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- People taking 5 or more medications, including over the counter drugs, supplements, natural products, cannabis produces, or other recreational drugs
- Ability to give and comprehend the consent process.
- Consent to donate urine samples, genetic data through buccal swabs, undergo a comprehensive history and physical examination.
- All genders.
- Age 45 and over
You will not qualify if you...
- Subject has been diagnosed or is being treated for any cancer other than basal cell cancer in the last 5 years. Patients with metastatic melanoma in the last 5 years will be excluded.
- Admitted to hospice.
- Patient has ever been diagnosed with Hepatitis B or C.
- Patient has ever been diagnosed with active liver disease, hepatomegaly, grossly abnormal liver function. Meld score >10, ALT or AST >100U/L or an AST/ALT ratio >2
- Patients taking imidazole antifungal medication.
- Declines to participate or interact with staff/share their medical status.
- A diagnosis of Alzheimer's disease
- Pregnant patients will be excluded
- Unable/unwilling to consent.
- Unable to verbally communicate and comprehend English/Spanish language.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Interprofessional Pharmacogenomics (IPGx) Clinic
Bryan, Texas, United States, 77802
Actively Recruiting
Research Team
K
Kenneth S Ramos, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here